SELLAS Life Sciences Group, Inc. (ETR:RXK3)
| Market Cap | 3.55B +1,926.6% |
| Revenue (ttm) | n/a |
| Net Income | -31.49M |
| EPS | -0.18 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 7,153 |
| Open | 6.88 |
| Previous Close | 7.02 |
| Day's Range | 6.88 - 18.65 |
| 52-Week Range | 7.02 - 18.70 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Est. Earnings | Mar 19, 2027 |
About ETR:RXK3
SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel therapeutics for various cancer indications in the United States. The company’s lead product candidate is galinpepimut-S (GPS), a peptide immunotherapy directed against the Wilms tumor 1, antigen; and SLS009 (tambiciclib), a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembroli... [Read more]
News
Sellas Life Sciences announces $150M common stock offering
Sellas Life Sciences (SLS) Group announced that it has commenced an underwritten public offering of $150M of shares of its common stock. All of the shares in the offering will…
SELLAS Life Sciences Announces Proposed $150.0 Million Underwritten Public Offering
NEW YORK, Nov. 17, 2026 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (Nasdaq: SLS) (“SELLAS” or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of no...
Sellas Life Sciences price target raised to $40 from $30 at Maxim
Maxim analyst Jason McCarthy raised the firm’s price target on Sellas Life Sciences (SLS) to $40 from $30 and keeps a Buy rating on the shares after the Phase 3…
Sellas Life Sciences trading resumes
09:45 EST Sellas Life Sciences (SLS) trading resumes
Sellas Life Sciences trading halted, volatility trading pause
09:35 EST Sellas Life Sciences (SLS) trading halted, volatility trading pause
Why SELLAS Life Sciences Stock Is Skyrocketing Over 200% Today — and What This Analyst Sees Next
SELLAS Life Sciences (NASDAQ:SLS) stock is skyrocketing more than 200% on Tuesday after the cancer drug developer announced positive results from its late-stage leukemia trial. The company’s experimen...
SELLAS Life Sciences Stock (SLS) Rockets 236% on Stellar Phase 3 Trial Results
SELLAS Life Sciences stock rocketed higher on Tuesday after the company published results from a clinical trial.
SELLAS Life Sciences Group Transcript: Study result
GPS met REGAL’s Phase III OS endpoint: median survival was 24 months vs. 14.7 months with BAT, with a 41% lower risk of death. Safety was favorable, and FDA discussions and BLA preparation are planned.
SELLAS Life Sciences Group Press release: Study result
SELLAS Life Sciences Group issued a press release on November 17, 2026, disclosing material business information to investors.
Sellas Life Sciences reports REGAL trial meets primary endpoint
Sellas Life Sciences (SLS) announced topline results from the pivotal randomized Phase 3 REGAL trial evaluating galinpepimut-S, or GPS, an immunotherapeutic cancer vaccine, in patients with acute myel...
Sellas' cancer vaccine extends survival in blood cancer trial
Drug developer Sellas Life Sciences said on Tuesday its experimental vaccine for a type of blood cancer helped patients live significantly longer in a late-stage trial, sparking a record one-day sur...
SELLAS Life Sciences Announces Positive Pivotal Phase 3 REGAL Trial Data Showing Immunotherapeutic Cancer Vaccine, Galinpepimut-S (GPS), Demonstrated a Statistically Significant and Clinically Meaningful Improvement in Overall Survival in Patients with Acute Myeloid Leukemia
- REGAL trial met its primary endpoint with GPS demonstrating statistically significant and clinically meaningful reduction in risk of death by 41% with median overall survival of 24.0 months versus 1...
SELLAS Life Sciences Reports Third Quarter 2026 Financial Results and Provides Corporate Update
- Topline Primary Endpoint Results of the Phase 3 REGAL Trial of Galinpepimut-S (GPS) in Acute Myeloid Leukemia Following the 80th Event to Report this Month - - 40 Patients Enrolled in Phase 2 Trial ...
SELLAS Life Sciences Group Quarterly report: Q3 2026
SELLAS Life Sciences Group has published its Q3 2026 quarterly earnings report on November 12, 2026.
SELLAS Life Sciences Group Earnings release: Q3 2026
SELLAS Life Sciences Group released its Q3 2026 earnings on November 12, 2026, summarizing the period's financial results.
SELLAS Life Sciences to Present Positive Phase 2 Data Demonstrating Encouraging Response and Survival Outcomes with SLS009 Combination in High-Risk AML at ASH 2026
− Company to present Phase 2 clinical data evaluating SLS009 (tambiciclib) in combination with azacitidine and venetoclax in patients who have previously failed venetoclax-based therapy − − Patients w...
Sellas Life Sciences falls -17.7%
Sellas Life Sciences (SLS) is down -17.7%, or -$2.15 to $10.02.
SELLAS Life Sciences Stock (SLS) Slides 18% as a Phase 3 Study Enters Its Evaluation Period
SELLAS Life Sciences stock dropped over 18% on Wednesday alongside a clinical trial update.
Sellas Life Sciences triggers final analysis of REGAL trial
Sellas Life Sciences (SLS) announced that the pivotal Phase 3 REGAL trial evaluating galinpepimut-S, or GPS, in patients with acute myeloid leukemia, or AML, has reached the pre-specified 80th event,…
SELLAS Life Sciences Reaches 80th Event in Phase 3 REGAL Trial of Galinpepimut-S (GPS) in Acute Myeloid Leukemia
- Reaching the Pre-Specified 80 th Event Triggers the Final Analysis of the Pivotal Phase 3 Trial -
Sellas Life Sciences falls -13.1%
Sellas Life Sciences (SLS) is down -13.1%, or -$1.49 to $9.85.
Sellas Life Sciences falls -12.5%
Sellas Life Sciences (SLS) is down -12.5%, or -$1.42 to $9.92.
Sellas Life Sciences put volume heavy and directionally bearish
Bearish flow noted in Sellas Life Sciences (SLS) with 9,677 puts trading, or 3x expected. Most active are Jan-27 10 puts and Oct-26 15 calls, with total volume in those…
Sellas Life Sciences presents preclinical data on SLS009 at AACR Conference
SELLAS Life Sciences (SLS) Group announced preclinical data from studies evaluating SLS009, its highly selective cyclin-dependent kinases 9 inhibitor, in patient-derived organoid models of pancreatic ...
SELLAS Life Sciences Presents Preclinical Data Demonstrating SLS009 Activity in Pancreatic Cancer Models at the 2026 AACR Conference on Pancreatic Cancer
NEW YORK, Sept. 25, 2026 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS'' or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of ...